Centerpoint Advisors’s Ocular Therapeutix OCUL Stock Holding History

Centerpoint Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,390	Closed	-$10K	–	627
2022 Q4	$10K	Hold	3,390	–	–	﹤0.01%	305
2022 Q3	$14K	Hold	3,390	–	–	0.01%	203
2022 Q2	$14K	Hold	3,390	–	–	0.01%	210
2022 Q1	$17K	Hold	3,390	–	–	0.01%	202
2021 Q4	$24K	Buy	3,390 +1,000	+42%	+$7.77K	0.01%	170
2021 Q3	$24K	Hold	2,390	–	–	0.01%	159
2021 Q2	$34K	Buy	2,390 +1,140	+91%	+$17.3K	0.02%	144
2021 Q1	$21K	Hold	1,250	–	–	0.01%	134
2020 Q4	$26K	Hold	1,250	–	–	0.02%	124
2020 Q3	$10K	Hold	1,250	–	–	0.01%	149
2020 Q2	$10K	Hold	1,250	–	–	0.01%	158
2020 Q1	$6K	Sell	1,250 -1,268	-50%	-$6.26K	0.01%	166
2019 Q4	$10K	Hold	2,518	–	–	0.01%	168
2019 Q3	$8K	Hold	2,518	–	–	0.01%	171
2019 Q2	$11K	Buy	+2,518	New	+$9.32K	0.01%	158

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Centerpoint Advisors's OCUL Position: Q1 2023 in Review

Centerpoint Advisors sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 3,390 shares — an estimated $10K sold.

Centerpoint Advisors first reported a position in OCUL in Q2 2019 and held it in 15 quarters. The position peaked at $34K in Q2 2021. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

Centerpoint Advisors reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
Centerpoint Advisors sold 3,390 Ocular Therapeutix shares in Q1 2023, an estimated $10K.
Centerpoint Advisors first reported a position in Ocular Therapeutix in Q2 2019 and held it in 15 quarters.
Centerpoint Advisors's Ocular Therapeutix position peaked at $34K in Q2 2021.
127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Centerpoint Advisors's 13F filing for Q1 2023, filed 3 May 2023.